A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Vertex Pharmaceuticals Incorporated
Related studies linked through entity extraction aliases.
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- Status
- COMPLETED
- Phase
- PHASE2
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
- Status
- COMPLETED
- Phase
- PHASE1
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
- Status
- COMPLETED
- Phase
- PHASE3
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
- Status
- COMPLETED
- Phase
- PHASE2
First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
- Status
- COMPLETED
- Phase
- PHASE1
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
- Status
- COMPLETED
- Phase
- PHASE2
First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
- Status
- TERMINATED
- Phase
- PHASE1
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
- Status
- TERMINATED
- Phase
- PHASE2